Thermo Fisher Scientific (NYSE:TMO) Price Target Lowered to $665.00 at Stifel Nicolaus

Thermo Fisher Scientific (NYSE:TMO) had its price objective trimmed by Stifel Nicolaus from $680.00 to $665.00 in a research report released on Thursday, Benzinga reports. The firm currently has a buy rating on the medical research company’s stock.

Several other research firms have also recently weighed in on TMO. Morgan Stanley increased their price objective on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Stephens started coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price objective for the company. Bank of America increased their price objective on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Monday, September 16th. Finally, Raymond James increased their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $649.33.

Thermo Fisher Scientific Trading Up 0.2 %

Shares of TMO stock traded up $1.10 during mid-day trading on Thursday, reaching $558.48. 242,854 shares of the stock traded hands, compared to its average volume of 1,463,320. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific has a 1-year low of $420.21 and a 1-year high of $627.88. The stock’s fifty day simple moving average is $606.12 and its two-hundred day simple moving average is $584.21. The company has a market cap of $213.34 billion, a price-to-earnings ratio of 34.72, a price-to-earnings-growth ratio of 3.75 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. During the same period in the prior year, the company posted $5.69 EPS. The company’s revenue was up .2% on a year-over-year basis. On average, research analysts anticipate that Thermo Fisher Scientific will post 21.72 EPS for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $76,420,473.36. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 6,300 shares of the firm’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $602.09, for a total transaction of $3,793,167.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,548,375.44. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is owned by insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

Large investors have recently modified their holdings of the business. Hedeker Wealth LLC grew its stake in Thermo Fisher Scientific by 3.2% during the third quarter. Hedeker Wealth LLC now owns 7,117 shares of the medical research company’s stock valued at $4,402,000 after acquiring an additional 221 shares in the last quarter. MONECO Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 1.5% in the 3rd quarter. MONECO Advisors LLC now owns 5,159 shares of the medical research company’s stock worth $3,191,000 after acquiring an additional 76 shares during the last quarter. Fortitude Family Office LLC lifted its holdings in shares of Thermo Fisher Scientific by 2.5% in the 3rd quarter. Fortitude Family Office LLC now owns 1,427 shares of the medical research company’s stock worth $883,000 after acquiring an additional 35 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Thermo Fisher Scientific by 132.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,372 shares of the medical research company’s stock worth $849,000 after buying an additional 781 shares during the period. Finally, Wilson Asset Management International PTY Ltd. increased its stake in shares of Thermo Fisher Scientific by 13.9% in the third quarter. Wilson Asset Management International PTY Ltd. now owns 26,219 shares of the medical research company’s stock worth $16,218,000 after buying an additional 3,197 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.